Alexander McGirr1, Frederique Van den Eynde2, Eduardo Chachamovich3, Marcelo P A Fleck2, Marcelo T Berlim4. 1. Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. 2. Neuromodulation Research Clinic, Douglas Mental Health University Institute, Montréal, QC, Canada. 3. Depressive Disorders Program, Douglas Mental Health University Institute and McGill University, Montréal, QC, Canada. 4. Depressive Disorders Program, Douglas Mental Health University Institute and McGill University, Montréal, QC, Canada; Neuromodulation Research Clinic, Douglas Mental Health University Institute, Montréal, QC, Canada. Electronic address: nrc.douglas@me.com.
Abstract
BACKGROUND: Prognostication is poor in repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder (MDD). Personality traits, particularly extraversion and neuroticism, have attracted increasing attention for both trait- and state-dependent characteristics in predicting response to pharmacotherapy, psychotherapy, and more recently to therapeutic neuromodulation for MDD. The advent of deep rTMS (DTMS) allows stimulation of deeper cortical regions, and we aimed to prospectively characterize personality dimensions and antidepressant response to DTMS in treatment-resistant MDD. METHODS: A convenience sample of 15 patients with treatment-resistant MDD received four weeks of daily sessions of DTMS (20 Hz, 3000 pulses/session) of the left dorsolateral prefrontal cortex (DLFPC). At baseline and at the conclusion of treatment, patients completed the Big Five Inventory, a five-factor assessment of major personality dimensions. Clinical response was measured using the 21-item Hamilton Depression Rating Scale. RESULTS: Four weeks of DTMS treatment were not associated with changes in personality measures. Clinical remission was associated with higher baseline levels of agreeableness (score ≥ 29:100% sensitive and 72.7% specific) and conscientiousness (score ≥ 30:75% sensitive and 81.8% specific). Levels of agreeableness and extraversion were linearly associated with antidepressant response. Neuroticism was not associated with the antidepressant effects of DTMS in this cohort. CONCLUSIONS: Five-factor personality assessment may have prognostic value in DTMS for resistant MDD. Agreeableness, extraversion, and conscientiousness are associated with decreases in depressive symptoms during treatment with DTMS.
BACKGROUND: Prognostication is poor in repetitive transcranial magnetic stimulation (rTMS) treatment for major depressive disorder (MDD). Personality traits, particularly extraversion and neuroticism, have attracted increasing attention for both trait- and state-dependent characteristics in predicting response to pharmacotherapy, psychotherapy, and more recently to therapeutic neuromodulation for MDD. The advent of deep rTMS (DTMS) allows stimulation of deeper cortical regions, and we aimed to prospectively characterize personality dimensions and antidepressant response to DTMS in treatment-resistant MDD. METHODS: A convenience sample of 15 patients with treatment-resistant MDD received four weeks of daily sessions of DTMS (20 Hz, 3000 pulses/session) of the left dorsolateral prefrontal cortex (DLFPC). At baseline and at the conclusion of treatment, patients completed the Big Five Inventory, a five-factor assessment of major personality dimensions. Clinical response was measured using the 21-item Hamilton Depression Rating Scale. RESULTS: Four weeks of DTMS treatment were not associated with changes in personality measures. Clinical remission was associated with higher baseline levels of agreeableness (score ≥ 29:100% sensitive and 72.7% specific) and conscientiousness (score ≥ 30:75% sensitive and 81.8% specific). Levels of agreeableness and extraversion were linearly associated with antidepressant response. Neuroticism was not associated with the antidepressant effects of DTMS in this cohort. CONCLUSIONS: Five-factor personality assessment may have prognostic value in DTMS for resistant MDD. Agreeableness, extraversion, and conscientiousness are associated with decreases in depressive symptoms during treatment with DTMS.
Authors: Daniel C Kopala-Sibley; Gabrielle B Chartier; Shiv Bhanot; Jaeden Cole; Peter Y Chan; Marcelo T Berlim; Alexander McGirr Journal: Can J Psychiatry Date: 2019-05-01 Impact factor: 4.356
Authors: Matias M Pulopulos; Sara De Witte; Marie-Anne Vanderhasselt; Rudi De Raedt; Johan Schiettecatte; Ellen Anckaert; Alicia Salvador; Chris Baeken Journal: PLoS One Date: 2019-10-16 Impact factor: 3.240
Authors: Eleanor M Wigmore; Jonathan D Hafferty; Lynsey S Hall; David M Howard; Toni-Kim Clarke; Chiara Fabbri; Cathryn M Lewis; Rudolf Uher; Lauren B Navrady; Mark J Adams; Yanni Zeng; Archie Campbell; Jude Gibson; Pippa A Thomson; Caroline Hayward; Blair H Smith; Lynne J Hocking; Sandosh Padmanabhan; Ian J Deary; David J Porteous; Ole Mors; Manuel Mattheisen; Kristin K Nicodemus; Andrew M McIntosh Journal: Pharmacogenomics J Date: 2019-01-31 Impact factor: 3.245
Authors: Rajamannar Ramasubbu; Laina McAusland; Sanchit Chopra; Darren L Clark; Bettina H Bewernick; Zelma H T Kiss Journal: J Psychiatry Neurosci Date: 2021-07-01 Impact factor: 6.186